Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK

Penserra Capital Management LLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 150,599 shares of the company’s stock, valued at approximately $3,539,000. Penserra Capital Management LLC owned 0.27% of Stoke Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Stoke Therapeutics by 14.1% in the second quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company’s stock valued at $171,000 after purchasing an additional 1,862 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after purchasing an additional 2,384 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.28, for a total value of $128,409.84. Following the completion of the sale, the general counsel directly owned 11,831 shares of the company’s stock, valued at approximately $381,904.68. This represents a 25.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 13,430 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.27, for a total transaction of $433,386.10. Following the transaction, the director owned 49,124 shares in the company, valued at approximately $1,585,231.48. This trade represents a 21.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 98,774 shares of company stock valued at $2,918,365 in the last three months. 9.50% of the stock is currently owned by company insiders.

Stoke Therapeutics Trading Down 4.8%

Shares of Stoke Therapeutics stock opened at $30.48 on Friday. The company has a fifty day simple moving average of $31.43 and a 200-day simple moving average of $26.06. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 45.49 and a beta of 1.10. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. On average, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on STOK shares. Canaccord Genuity Group lifted their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Needham & Company LLC lifted their price target on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a report on Monday, December 15th. Loop Capital set a $35.00 price objective on shares of Stoke Therapeutics in a report on Monday, January 5th. Finally, Chardan Capital boosted their target price on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $39.18.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.